ADA: Merck, Pfizer’s Steglatro rings up CV safety win, but it still lags heart-helping peers
Merck and Pfizer’s Steglatro, late the SGLT2 party, has been working to catch up to its in-class rivals, which already bear heart-helping approvals. But it’s cardiovascular outcomes data won’t help it get on their level. Steglatro showed it could match placebo when it comes to the combined rate of heart attack, stroke and cardiovascular death… Read More: ADA: Merck, Pfizer’s Steglatro rings up CV safety win, but… »